Neubond

Neubond operates at the intersection of neurorehabilitation, medical devices, digital health, and wearable technology. Its stated focus is stroke mobility rehabilitation, with devices intended to provide autonomous assistance and therapy during everyday activities rather than limiting treatment to scheduled clinical sessions. That gives the company a distinctive care-delivery thesis: increase rehabilitation intensity and continuity by moving parts of therapy into the home. The company also emphasizes patient-centred design, lived-experience input from stroke support groups, and cross-disciplinary expertise spanning electrical engineering, bioengineering, mechanical engineering, neuroscience, software, and clinical rehabilitation. The available comparison information does not identify named competitors, so Neubond cannot be ranked directly against specific companies on funding, regulatory progress, installed base, or clinical outcomes. Its competitive differentiation is therefore best understood through product intent and team composition rather than demonstrated scale. Compared with conventional clinic-bound rehabilitation, Neubond targets accessibility and daily-use continuity; compared with general-purpose wearables, it is pursuing therapeutic assistance for neurological recovery. Its $2.89 million in cumulative funding and 1–10 employee band indicate an early-stage specialist position, with validation and commercialization still ahead.

Neubond’s trajectory shows a progression from research and grant support toward a more commercially oriented seed-backed medical-device program. The company received a $388,479 grant announced on May 31, 2024, followed by a $525,831 grant dated Jan 1, 2025. On Jun 24, 2026, it secured a $1,973,645 seed round led by WASEDA University Ventures, bringing cumulative disclosed funding to $2,887,955 across three rounds. The sequence suggests increasing investor commitment, with private seed capital becoming the largest financing event after public and institutional grant support. Hiring plans provide a second inflection point. Recruiting a Research Physiotherapist or Occupational Therapist indicates attention to clinical workflow, patient assessment, and rehabilitation evidence, while hiring a Production & Manufacturing Engineer suggests movement toward repeatable device production. The founding team’s combination of clinical-scientific leadership and engineering capability supports that transition: Patrick Sagastegui Alva leads as CEO, Jumpei Kashiwakura as CTO, and Dario Farina as scientific advisor. However, public information does not establish regulatory clearance, revenue, product-launch dates, or employee growth beyond the current 1–10 employee range. Growth is therefore best characterized as funded development and team-building rather than proven commercial scale.